1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
  5. > Global Oncology Analysis & Statistics (p2)

Global Oncology Analysis & Statistics (p2)

31-60 of about 1800 reports

Neoantigen Targeted Therapies Market Research Report by Target Disease Indication, by Neoantigens Type, by Immunotherapy Type, by Route of Administration, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • June 2021
  • 189 pages

Neoantigen Targeted Therapies Market Research Report by Target Disease Indication (Bone Cancer, Colorectal Cancer, and Gynecological Cancer), by Neoantigens Type (Off-the-shelf Neoantigens and Personalized ...

  • World
  • APAC
  • Targeted Therapy
  • Industry analysis

Oncology Biosimilars Market Research Report by Application, by End-User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • June 2021
  • 198 pages

Oncology Biosimilars Market Research Report by Application (Cancer Treatment Drugs and Supportive Care Drugs), by End-User (Hospitals and Retail Pharmacies), by Region (Americas, Asia-Pacific, and Europe, ...

  • World
  • APAC
  • Pharmacy
  • Oncology
  • Industry analysis

Oncology Drugs Market Research Report by Indication, by Drug Class Type, by Distribution, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • June 2021
  • 185 pages

Oncology Drugs Market Research Report by Indication (Bladder Cancer, Breast Cancer, and Cervical Cancer), by Drug Class Type (Chemotherapy, Hormonal Therapy, and Immunotherapy), by Distribution, by Region ...

  • World
  • APAC
  • Breast Cancer
  • Pharmacy
  • Industry analysis

Protein Labeling Market Research Report by Product, by Labeling Method, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • June 2021
  • 192 pages

Protein Labeling Market Research Report by Product (Kits, Reagents, and Services), by Labeling Method (Bioorthogonal Labeling, In Vitro Labeling Methods, and In Vivo Labeling Methods), by Application, ...

  • World
  • APAC
  • Marketing Research
  • Research And Development
  • Industry analysis

Research Antibodies Market Research Report by Function, by Operation, by Product, by Source, by Technology, by Type, by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • June 2021
  • 191 pages

Research Antibodies Market Research Report by Function (Immunology, Infectious Diseases, and Neurobiology), by Operation (Drug Development, Genomics, and Proteomics), by Product, by Source, by Technology, ...

  • World
  • APAC
  • Infectious Disease
  • Drug Development
  • Industry analysis

Veterinary Oncology Market Research Report by Therapy, by Animal Type, by Cancer Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • June 2021
  • 199 pages

Veterinary Oncology Market Research Report by Therapy (Chemotherapy, Immunotherapy, and Radiology), by Animal Type (Canine and Feline), by Cancer Type, by Region (Americas, Asia-Pacific, and Europe, ...

  • World
  • APAC
  • Marketing Research
  • Research And Development
  • Industry analysis

Global Electroporation Instruments Market 2021-2025

  • $ 2500
  • May 2021
  • 120 pages

Global Electroporation Instruments Market 2021-2025 The analyst has been monitoring the electroporation instruments market and it is poised to grow by $ 87.59 mn during 2021-2025, progressing at a CAGR ...

  • World
  • Monoclonal Antibody
  • Marketing Research
  • Industry analysis

Radiotherapy Devices Global Market Report 2021: COVID 19 Growth And Change to 2030

  • $ 5000
  • May 2021
  • 175 pages

Major players in the radiotherapy devices market are Varian Medical Systems, Elekta AB, Accuray Inc., C.R.Bard Inc., IBA Ion Beam Applications SA, Koninklijke Philips N.V., Siemens AG, Eckert & Ziegle ...

  • United States
  • World
  • Oncology
  • Artificial Intelligence
  • Industry analysis

Axial spondyloarthritis - Pipeline Insight, 2021

  • $ 2000
  • May 2021
  • 80 pages

“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline ...

  • World
  • Monoclonal Antibody
  • Therapy
  • Industry analysis

Global Cancer Vaccine Partnering Terms and Agreements 2010-2021

  • $ 3495
  • May 2021
  • 250 pages

The Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading ...

  • World
  • Cancer Immunotherapy
  • Industry analysis

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2021

  • $ 3495
  • May 2021
  • 400 pages

The Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2021 report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into ...

  • World
  • Monoclonal Antibody
  • Industry analysis

AXL Kinase inhibitor - Pipeline Insight, 2021

  • $ 2000
  • May 2021
  • 100 pages

“AXL Kinase inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in AXL Kinase inhibitor pipeline landscape. It covers the pipeline ...

  • World
  • Targeted Therapy
  • Industry analysis

Global Doxorubicin Industry

  • $ 5600
  • May 2021
  • 215 pages

Abstract: - Global Doxorubicin Market to Reach US$1.4 Billion by the Year 2027 - Amid the COVID-19 crisis, the global market for Doxorubicin estimated at US$992.8 Million in the year 2020, is projected ...

  • World
  • China
  • Chemotherapy
  • Industry analysis

Global mRNA Vaccines Industry

  • $ 5600
  • May 2021
  • 125 pages

Abstract: - Global mRNA Vaccines Market to Reach $127.3 Billion by 2027 - Amid the COVID-19 crisis, the global market for mRNA Vaccines estimated at US$64.9 Billion in the year 2021, is projected to ...

  • World
  • China
  • Cancer Immunotherapy
  • Vaccine
  • Industry analysis

Paroxysmal nocturnal haemoglobinuria - Pipeline Insight, 2021

  • $ 2000
  • May 2021
  • 100 pages

“Paroxysmal nocturnal haemoglobinuria - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Paroxysmal nocturnal haemoglobinuria pipeline landscape. ...

  • World
  • Monoclonal Antibody
  • Therapy
  • Industry analysis

Neutropenia - Pipeline Insight, 2021

  • $ 2000
  • May 2021
  • 60 pages

“Neutropenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including ...

  • World
  • China
  • Clinical Trial
  • Monoclonal Antibody
  • Industry analysis

Chemotherapy Induced Myelosuppression (Oncology) - Drugs in Development, 2021

  • $ 2000
  • April 2021
  • 35 pages

Chemotherapy Induced Myelosuppression (Oncology) - Drugs in Development, 2021 Summary Chemotherapy Induced Myelosuppression (Oncology) - Drugs in Development, 2021 provides an overview of the Chemotherapy ...

  • World
  • Chemotherapy
  • Therapy
  • Industry analysis

Chemotherapy-Induced Diarrhea (CID) (Toxicology) - Drugs in Development, 2021

  • $ 2000
  • April 2021
  • 30 pages

Chemotherapy-Induced Diarrhea (CID) (Toxicology) - Drugs in Development, 2021 Summary Chemotherapy-Induced Diarrhea (CID) (Toxicology) - Drugs in Development, 2021 provides an overview of the Chemotherapy-Induced ...

  • World
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Industry analysis

Chemotherapy Induced Pain (Central Nervous System) - Drugs in Development, 2021

  • $ 2000
  • April 2021
  • 35 pages

Chemotherapy Induced Pain (Central Nervous System) - Drugs in Development, 2021 Summary Chemotherapy Induced Pain (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Chemotherapy ...

  • World
  • Neurology
  • Chemotherapy
  • Industry analysis

Chemotherapy Induced Oral Mucositis (Toxicology) - Drugs in Development, 2021

  • $ 2000
  • April 2021
  • 40 pages

Chemotherapy Induced Oral Mucositis (Toxicology) - Drugs in Development, 2021 Summary Chemotherapy Induced Oral Mucositis (Toxicology) - Drugs in Development, 2021 provides an overview of the Chemotherapy ...

  • World
  • Chemotherapy
  • Therapy
  • Industry analysis

Chemotherapy Effects (Toxicology) - Drugs in Development, 2021

  • $ 2000
  • April 2021
  • 90 pages

Chemotherapy Effects (Toxicology) - Drugs in Development, 2021 Summary Chemotherapy Effects (Toxicology) - Drugs in Development, 2021 provides an overview of the Chemotherapy Effects pipeline landscape. The ...

  • World
  • Chemotherapy
  • Therapy
  • Industry analysis

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drugs in Development, 2021

  • $ 3000
  • April 2021
  • 70 pages

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drugs in Development, 2021 Summary Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein ...

  • World
  • Monoclonal Antibody
  • Industry analysis

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drugs in Development, 2021

  • $ 3500
  • April 2021
  • 270 pages

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drugs in Development, 2021 Summary Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drugs in Development, 2021 provides in depth analysis ...

  • World
  • Cancer Immunotherapy
  • Industry analysis

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021

  • $ 3000
  • April 2021
  • 55 pages

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021 Summary CD40 Ligand (T Cell Antigen ...

  • World
  • Immunotherapy
  • Monoclonal Antibody
  • Industry analysis

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drugs in Development, 2021

  • $ 3000
  • April 2021
  • 75 pages

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drugs in Development, 2021 Summary Tumo ...

  • World
  • Monoclonal Antibody
  • Industry analysis

Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Drugs in Development, 2021

  • $ 3000
  • April 2021
  • 45 pages

Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Drugs in Development, 20 ...

  • World
  • Monoclonal Antibody
  • Industry analysis

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Drugs in Development, 2021

  • $ 3000
  • April 2021
  • 35 pages

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Drugs ...

  • World
  • Immunotherapy
  • Cell Therapy
  • Industry analysis

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drugs in Development, 2021

  • $ 3500
  • April 2021
  • 300 pages

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drugs in Development, 2021 Summary Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drugs in Development, 2021 provides ...

  • World
  • Cancer Immunotherapy
  • Industry analysis

Tumor Necrosis Factor Ligand Superfamily Member 11 - Drugs in Development, 2021

  • $ 3000
  • April 2021
  • 80 pages

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin ...

  • World
  • Monoclonal Antibody
  • Industry analysis

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Drugs in Development, 2021

  • $ 3000
  • April 2021
  • 65 pages

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Drugs in Development, 20 ...

  • World
  • Monoclonal Antibody
  • Industry analysis
About 2300 reports

Download Unlimited Documents from Trusted Public Sources

View report >

Global Oncology Market Trends

  • June 2021
  • 34 pages
  • World
  • Oncology
  • Cancer
  • Industry analysis
  • Life Expectancy
  • Surgical Procedures Performed

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on